ADMA Biologics, Inc.
ADMA
$16.57
-$0.02-0.09%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -55.87% | 1.45% | 6.72% | 51.10% | 734.15% |
| Total Depreciation and Amortization | 5.25% | 4.28% | 0.54% | -6.86% | -7.82% |
| Total Amortization of Deferred Charges | -10.05% | -32.54% | -29.52% | -24.90% | -68.62% |
| Total Other Non-Cash Items | 108.43% | 280.55% | 172.43% | 276.55% | -369.04% |
| Change in Net Operating Assets | -264.10% | -130.03% | -371.24% | -131.46% | 280.77% |
| Cash from Operations | -29.03% | -46.89% | -53.69% | -787.06% | 185.37% |
| Capital Expenditure | 60.68% | -1,260.61% | -17.23% | -100.30% | -130.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11,442.86% | 100.00% | 64.88% | -26.67% | 103.33% |
| Cash from Investing | 89.96% | -1,208.56% | -6.85% | -99.83% | -95.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 98.44% | -151.56% | -- | -- | 81.08% |
| Issuance of Common Stock | -2.93% | -93.16% | 523.56% | -90.18% | 5,437.50% |
| Repurchase of Common Stock | -1,307.76% | -1,972.71% | -71.86% | -191.92% | -88.86% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 98.42% | -- | -- | -- | 94.53% |
| Cash from Financing | 70.61% | -9.26% | 113.26% | -392.54% | 20.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 59.64% | -1,780.29% | -56.52% | -423.01% | 172.09% |